Compare Cytokinetics Inc (CYTK) vs Quanta Services Inc (PWR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs Quanta Services Inc — how do they compare? Cytokinetics Inc trades at $62.69 (market cap $8.62B), while Quanta Services Inc trades at $700.31 (market cap $103.03B). The key difference: Quanta Services Inc is far larger — about 12× Cytokinetics Inc's market cap, and Quanta Services Inc pays a 0.06% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and Quanta Services Inc for 62 Days on average.
| CYTK | PWR | |
|---|---|---|
Market Cap | $8.62B | $103.03B |
Volume | 2,594,626 | 977,892 |
Sector | Health | Industrials |
52-Week High | $87.26 | $785.24 |
52-Week Low | $54.76 | $412.21 |
Typical Hold Time | 19 Days | 62 Days |
Enterprise Value | $8.72B | $109.13B |
Dividend Yield | — | 0.06% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
PWR trades at $705.94, up 0.69% today, with a bullish technical signal and strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, reaching $28.48B in 2025, though valuation multiples like a P/E of 78.41 appear elevated. Positive sentiment is driven by a record $53B backlog and AI infrastructure demand, as highlighted in recent Zacks reports.
Outlook remains positive given earnings momentum and sector tailwinds, but high valuation and execution risks from rapid expansion warrant caution. The consensus price target of $802.08 implies upside, yet investors should monitor margin sustainability and competitive pressures in the construction and electrical services sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About Quanta Services Inc
Quanta Services is a leading provider of specialty contracting services, delivering comprehensive infrastructure solutions for the electric and gas utility, communications, pipeline, and energy industries in the United States, Canada, and Australia. Quanta reports its results under two reportable segments: electric power infrastructure solutions and underground utility and infrastructure solutions. In October 2021, the company completed the acquisition of Blattner, a provider of comprehensive engineering, procurement, and construction solutions to customers in the renewable energy industry.
Read more on PWR →
